Eisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment Leqembi (lecanemab-irmb) after the US Food and Drug Administration (FDA) ...

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESAIY) announced that the U.S. Food and Drug Administration (FDA) ...

Advisory group guidance enables nonprofit to be at the forefront of Alzheimer's research WELLESLEY HILLS, MA / ACCESSWIRE / ...

DMTs are expected to account for 73.5% of the global market. The global Alzheimer's disease (AD) market across the eight ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

To date, Leqembi has been approved in the US, Japan, China, South Korea, Hong Kong, Israel, UAE, GB, Mexico, and Macau, and ...

The lifetime risk of dementia after age 55 is about 42% - more than double the risk reported by earlier studies, and one that puts greater urgency on the need to mitigate addressable health problems, ...

Against the backdrop of the 43rd Annual J.P. Morgan Healthcare Conference, Mayo Clinic announced the formation of Mayo Clinic Digital Pathology, designed on a platform architecture to boldly unlock ...

“There are things that we can do at all stages of our lives deliberately,” says Prof Schott. “It’s never too early to start ...

New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according ...

In a finding with implications for one of the most promising cutting-edge medical treatments, researchers evaluated several measurement techniques commonly used in gene therapy.

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) said that the U.S. Food and Drug Administration has accepted Eisai's Biologics ...